

Monthly News – July 2011

Department of Psychiatry

June 12, 2011 Volume 5, Number 7

2011 Graduation Banquet:

Congratulations to all of our 2011 Resident and Fellow graduates and to the award recipients honored at the dinner:

Faculty of the Year Award

Dr. Cathleen Cerny

Excellence in Teaching Award

David Hahn, MD (Residency)
Felipe Amunategui, PhD (Child and Adolescent Psychiatry Fellowship)

Outstanding Nurse Awards

Debbie Ludwig, RN
Beverly Purcell, RN

Outstanding Resident Award

Megan Testa, MD

Community Psychiatry Award

Archana Brojmohun, MD
David Liu, MD

Mahmound A. Parsa Research Award

Weronika Micula-Gondek, MD

Class Excellence in Teaching

PGY-1 *Irina Korobkova, MD*
PGY-2 *Peter Corpus, MD*
PGY-3 – *Jeffrey Janata, PhD*
PGY-4 -- *Norman Clemens, MD*

Awards and Recognition:

Robert Garcowski, M.Ed.,
Therapeutic Program Lead for the

inpatient psychiatry units, will be inducted into the Hall of Merit at the 2011 Crisis Prevention Institute's International Instructor's annual award's banquet on Thursday, July 21st in Orlando Florida.

Congratulations:

Luciana Jackson, Patient Access Representative, celebrated her third anniversary with the Department of Psychiatry.

To PGY-3 resident **Sonal Moratschek** and her husband, Chris, on the birth of their daughter. Lyla Jane Moratschek was born on 6/16/11 at 9:38pm. She was 6 lbs and 8 oz and 20 inches long.



Comings and Goings:

New Faculty Members:

Jaina Amin
Senior Instructor

Community Psychiatry

Andrew Hunt
Senior Instructor
Community Psychiatry
Solomon Zaraa, DO
Senior Instructor
Child and Adolescent Psychiatry

Welcome to the new residents and fellows:

PGY-1 Residents:

Jae Kennedy-Cookson, MD
Smita Ramesh Gautam, MD
Michelle Elizabeth John, DO
Jacob McGrath, MD
Ming Ren, MD
Shree Nitya Sarathy, MD
Mauran Sivinanthan, DO
Elise Weinberger, MD

Addiction Psychiatry Fellow

Peter Turkson, DO

Child Psychiatry Fellows

Smitha Battula, MD
Priti Pursuhothaman, MD
Shelah Rote, JD, MD
Crystal Thomas, MD

Community Psychiatry Fellows:

Kirk Carruthers, MD
Michelle, Fulk, DO

Forensic Psychiatry Fellows:

John Lyszczarz, MD
Jennifer Piel, MD
Megan Testa, MD
Joseph Vlaskovits, MD

Post Pediatric Portal:

Mary Gabriel, MD
Richard Linsk, MD, Ph.D.

Child and Adolescent Psychiatry Inpatient Unit:

Stephanie Estok, Nursing Asst 2

Ann Baek, Intake Specialist

Grand Rounds:

July 15th:

Topic: Pregnancy/Depression or
Psychosis

Speaker: Ruth Graupera-Frain,
M.D.

July 22nd:

Topic: The Theory of Evolution:
What Does it Offer Psychiatry?

Speaker: David Robinson, M.D.

July 29th:

Topic: Paging Dr. Google:
Psychiatry and the Internet

Speakers: Cathleen Cerny, M.D.,
Molly McVoy, M.D. and Libbie
Stansifer, M.D.

August 5th:

Topic: Trauma, Triggers, and
Suicide Prevention; Conceptualizing
the Standard of Care

Speaker: Cheryl Wills, M.D.

August 12th:

Topic: Reimagining Care Delivery
in Community Mental Health

Presenter: Patrick Runnels, MD

August 19th:

Topic: The Opiate Epidemic in
Ohio: What Psychiatrists Can Do

Presenter: Christina Delos Reyes,
M.D.

Presentations and Publications:

**Ray Isackila and Judy Majcen of
Addiction Recovery Services** will
speak at the 10th Annual
Association of Recovery Schools
Annual Conference - "Rock & Roll

to Recovery"

Case Western Reserve University is proud to host the 10th Annual Association of Recovery Schools on July 20, 21, 22. The conference theme, Rock & Roll to Recovery, provides an opportunity to acknowledge the powerful nature of addiction and how our society, including the music world, has suffered. The conference acknowledges the educators, guidance counselors, social workers, psychologists, nurses, physicians, community volunteers, families and friends ... all who help young people in recovery pursue their dreams.

For more information go to

www.rockandrolltorecovery.com



**Carter, R.R., Johnson, S.M.,
Pagano, M.E.** (2011,
June). *Comparison of prosocial behavior
amongst adults with and without
substance dependency*. Poster presented
at the 34th annual meeting of the
Research Society on Alcoholism in
Atlanta, GA.

**Johnson, S.M., Carter, R.R.,
Pagano, M.E.** (2011, June). *Sexual
abuse, risky sexual behaviors and sexual
beliefs among substance dependent
adolescents court-referred to residential
treatment*. Poster presented at the
34th annual meeting of the
Research Society on Alcoholism in
Atlanta, GA.

**Pagano, M.E., Kelly, J.F.,
Johnson, S.M., Post, S.G., Stout,
R.L.** (2011, June). *The influence of
religiosity on 12-Step engagement and
substance use disorder treatment response
among adolescents*. Poster presented at
the 34th annual meeting of the
Research Society on Alcoholism
in Atlanta, GA.

**Pagano, M.E., Kelly, J.F.,
Johnson, S.M., Post, S.G., Stout,
R.L.** (Accepted for
Publication). The influence of
religiosity on 12-Step engagement
and substance use disorder
treatment response among
adolescents. *Journal of Studies on
Alcohol and Drugs*.

Research:

**The Discovery and Wellness
Center for Children** is in full swing
with the LAMS (Longitudinal
Assessment of Manic Symptoms)
study. **Dr. Robert Findling** was
awarded a \$7.8 million grant from
the NIMH for the continuation of
this study—launched 5 years ago—
in which children were screened and
evaluated for elevated symptoms of
mania over time.

The DWCC is very excited that
during the continuation of this
study they will be conducting
neuroimaging (fMRI) and
neurocognitive testing to see how
the youth already enrolled in LAMS
process information and pay
attention. These additional tests
will possibly help to identify
biomarkers to see if individuals are
predisposed to bipolar disorder.

The DWCC is well underway with
the neurocognitive testing and
neuroimaging components of the
LAMS study, and is now ready to
start recruiting for the "healthy
controls" for the neuroimaging
study. Before reaching out to the
community, the DWCC would like
to offer this unique opportunity to
anybody you know (friends or
family members) that may be
interested.

If you know of a child or adolescent
who meets the criteria below, please
call Becky Weintraub at 216-844-
3922 for more details.

The DWCC is looking for four (4)
13-16 year old males; four (4) 13-16
year old females; four (4) 9-12 year

old males and four (4) 9-12 year old females.

Inclusion Criteria:

- (1) Children must be living with a parent or guardian who has knowledge of the mental health history of child's 1st and 2nd degree relatives.

Exclusion Criteria:

- (1) Severe systemic medical illnesses
- (2) Neurological disorders
- (3) History of head trauma with loss of consciousness
- (4) Use of medications for medical illness that produce CNS effects (i.e. steroids)
- (5) Contraindications to MR scanning (pregnancy); claustrophobia; youth who have cardiac pacemakers, neural pacemakers, surgical clips in the brain or blood vessels, surgically implanted metal plates ,screws, pins, metal dental braces or other metal objects in their body. X-Rays will not be performed on youth in the study.
- (6) Positive urine drug and /or salivary alcohol screen on the day of the MR scan
- (7) Visual disturbance, determined by less than 20/40 Rosenbaum visual acuity that is not corrected by contact lenses or eye glasses.
- (8) Unable to complete questionnaires written in English
- (9) Autistic spectrum disorders or development delays
- (10) Individuals larger than 55" around shoulders and widest part of chest
- (11) Youth with motor tics.
- (12) Lifetime DSM-IV psychiatric diagnosis
- (13) 1st degree relative with a history of recurrent unipolar depressions, mania, hypomania or psychosis

- (14) 2nd degree relatives with a history of mania, hypomania or psychosis
- (15) IQ < 70 as assessed by the Wechsler Abbreviated Scale of Intelligence (WASI)

In addition to the 16 controls mentioned above, the DWCC is looking for 9 more controls, ages 8 to 17, that will travel to two other sites (Pittsburgh and Cincinnati) to be imaged there as well (a total of three scans).

Again, contact Becky Weintraub at 216-844-3922 for more details

Research Study:

Do you have patients with **schizophrenia** and previous **trouble with the law?**

This is a multicenter, 15-month, prospective, randomized, active-controlled, open-label, flexible dose study of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to treatment failure in adults with schizophrenia who have been recently released from custody/jail. Participants will be randomly assigned to receive either long-acting injectable or oral antipsychotic. ***Participants should continue to receive mental health and medical services from their usual providers while in the study.***

To participate, individuals must:

1. Be age 18 or older with schizophrenia;
2. Have been incarcerated (jail or prison) at least twice in the previous 2 years with the last release from the most recent incarceration occurring within the previous 90 days
3. Be able to provide written, informed consent to study participation.

To participate, individuals may NOT:

1. Women who are pregnant or breast-feeding, or planning to become pregnant
2. Subjects who are actively abusing intravenous drugs within the past 3 months
3. Have previous history of lack of response when treated with paliperidone

Contact Person

Tiffany Williams --216-844-2835

Email:

Tiffany.Williams@UHHospitals.org

Research Study:

Do you have patients with **bipolar disorder** who occasionally miss a dose of their medication and are concerned about **weight gain related to their current medication(s)**?

This is an open-label, 12-week, uncontrolled prospective trial of ziprasidone treatments among sub-optimally adherent patients with bipolar disorder. Psychotropic-related weight gain is a common concern among patients with bipolar disorder (BD). This concern affects an individual's satisfaction with treatment and may lead to reduced adherence and illness relapse.

The project will evaluate how switching to ziprasidone may affect patient adherence, drug attitudes, satisfaction with care, and clinical outcomes (psychiatric symptoms, functional status, weight) among BD patients concerned with weight gain.

*Study team will obtain support for ziprasidone switching for the identified psychotropic from the **patient's current care provider who will continue to see the patient and will continue to prescribe other drugs at unchanged dose.***

To participate, individuals must:

1. Have had a diagnosis of Type I or II BD for at least 6 months
2. Be on maintenance evidence-based treatment for BD

- (lithium, antipsychotic, anticonvulsant).
3. Have weight gain concerns that the individual believes are related to BD medication treatment.
 4. Have sub-optimal adherence.

To participate, individuals may NOT:

1. Be on ziprasidone immediately prior to study enrollment
2. Have current substance *dependence*.
3. Be at high risk of harm to self or others.
4. Be a female who is currently pregnant or breastfeeding.

Contact Person

Melanie Currens -- 216-844-2825
 Email: Melanie.Currens@UHhospitals.org

The **Mood Disorders Program** at University Hospitals Case Medical Center is currently looking for research participants between the ages of 18-75 to enroll in a study for an investigational medication for Bipolar I Disorder. Participants must be currently depressed, taking lithium or depakote for at least the past 4 weeks and not have an Axis I or Axis II diagnosis other than bipolar disorder that has been the primary focus of treatment within 3 months of screening. This study lasts up to 8 weeks and visits are once a week. If eligible for the study, participants may receive study-related medical care, research medication and an evaluation at no cost. If you would like more information about this study or any other studies we have ongoing at the Mood Disorders Program contact Carla Conroy, BA, CCRC at (216) 844-2871 or Carla.Conroy@UHhospitals.org

The **Mood Disorders Program** at University Hospitals Case Medical Center is currently looking for research participants between the ages of 18-65 to enroll in a study for an investigational medication for Bipolar I Disorder. Participants

must be currently depressed, taking lithium, valproic acid, lamotrigine, aripiprazole, olanzapine, risperidone or ziprasidone (only if taken in combination with lithium or valproic acid) for a minimum 4 weeks before the onset of their current major depressive episode and not have an Axis I or Axis II diagnosis other than bipolar disorder that has been the primary focus of treatment within 3 months of screening. This study may last up to 15 weeks and visits are once a week. If eligible for the study, participants may receive study-related medical care, research medication and an evaluation at no cost. If you would like more information about this study or any other studies we have ongoing at the Mood Disorders Program contact Carla Conroy, BA, CCRC at (216) 844-2871 or Carla.Conroy@UHhospitals.org

Save the date:

Department Meeting
Friday, September 2, 2011
 W.O. Walker Auditorium
 8:00 a.m. – 9:00 a.m.
 The Annual Department Photograph will be taken immediately following the meeting.

Annual Department Picnic
Sunday, September 25, 2011
 Squire Vallevue Farm
 3:00 – 7:00 p.m.
 To RSVP and for more information Contact:
Cynthia.Glenn@uhhospitals.org

NAMIWALKS 2011
Saturday, September 24, 2011

- **Location:** Voinovich Park behind the Rock & Roll Hall of Fame in Cleveland, OH
- **Date:** September 24, 2011
- **Check-in:** 9:00AM - Start Time: 10:00AM
- **Distance:** 2.5 MI
- **Check-in:** 9:00 am **Start:** 10:00 am

For additional information about participating in the Walk, contact Bridget Murphy at 216.875.0266 or via email at: bmurphy@nami.org

Sunday, October 2, 2011
 Suicide Prevention Education Alliance (SPEA) “Into the Light” walk at the Cleveland Zoo.
 For more information:
<http://www.speancobio.org/about/contact-spea>

Contact:
Published by University Hospitals Dept. of Psychiatry
DEADLINE FOR NEXT ISSUE: Friday, 08/12/2011
CONTACT: Kate Kilbane
 Phone: 216-844-3658
kate.kilbane@uhhospitals.org